D-serine levels in Alzheimer's disease: implications for novel biomarker development

Imagem de Miniatura
Arquivos
art_MADEIRA_Dserine_levels_in_Alzheimers_disease_implications_for_novel_2015.PDF (1.11 MB)
Citações na Scopus
174
Tipo de produção
article
Data de publicação
2015
Editora
NATURE PUBLISHING GROUP
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
MADEIRA, C.
LOURENCO, M. V.
VARGAS-LOPES, C.
BRANDAO, C. O.
REIS, T.
LAKS, J.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
TRANSLATIONAL PSYCHIATRY, v.5, article ID e561, 9p, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Alzheimer's disease (AD) is a severe neurodegenerative disorder still in search of effective methods of diagnosis. Altered levels of the NMDA receptor co-agonist, D-serine, have been associated with neurological disorders, including schizophrenia and epilepsy. However, whether D-serine levels are deregulated in AD remains elusive. Here, we first measured D-serine levels in post-mortem hippocampal and cortical samples from nondemented subjects (n = 8) and AD patients (n = 14). We next determined D-serine levels in experimental models of AD, including wild-type rats and mice that received intracerebroventricular injections of amyloid-beta oligomers, and APP/PS1 transgenic mice. Finally, we assessed D-serine levels in the cerebrospinal fluid (CSF) of 21 patients with a diagnosis of probable AD, as compared with patients with normal pressure hydrocephalus (n = 9), major depression (n = 9) and healthy controls (n = 10), and results were contrasted with CSF amyloid-beta/tau AD biomarkers. D-serine levels were higher in the hippocampus and parietal cortex of AD patients than in control subjects. Levels of both D-serine and serine racemase, the enzyme responsible for D-serine production, were elevated in experimental models of AD. Significantly, D-serine levels were higher in the CSF of probable AD patients than in non-cognitively impaired subject groups. Combining D-serine levels to the amyloid/tau index remarkably increased the sensitivity and specificity of diagnosis of probable AD in our cohort. Our results show that increased brain and CSF D-serine levels are associated with AD. CSF D-serine levels discriminated between nondemented and AD patients in our cohort and might constitute a novel candidate biomarker for early AD diagnosis.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/13398
Referências
  1. Vargas-Lopes C, 2011, J NEUROCHEM, V116, P281, DOI 10.1111/j.1471-4159.2010.07102.x
  2. Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100
  3. Wolosker H, 1999, P NATL ACAD SCI USA, V96, P721, DOI 10.1073/pnas.96.2.721
  4. Puzzo D, 2009, J NEUROSCI, V29, P8075, DOI 10.1523/JNEUROSCI.0864-09.2009
  5. Shankar GM, 2007, J NEUROSCI, V27, P2866, DOI 10.1523/JNEUROSCI.4970-06.2007
  6. Jurgensen S, 2011, J BIOL CHEM, V286, P3270, DOI 10.1074/jbc.M110.177790
  7. Sebollela A, 2012, J BIOL CHEM, V287, P7436, DOI 10.1074/jbc.M111.298471
  8. Reis T, 2012, CNS NEUROSCI THER, V18, P524, DOI 10.1111/j.1755-5949.2012.00311.x
  9. Mustafa AK, 2010, J NEUROSCI, V30, P1413, DOI 10.1523/JNEUROSCI.4297-09.2010
  10. Diniz LP, 2012, J BIOL CHEM, V287, P41432, DOI 10.1074/jbc.M112.380824
  11. Calcia MA, 2012, SCHIZOPHR RES, V142, P83, DOI 10.1016/j.schres.2012.09.014
  12. Panizzutti R, 2001, P NATL ACAD SCI USA, V98, P5294, DOI 10.1073/pnas.091002298
  13. Ownby RL, 2006, ARCH GEN PSYCHIAT, V63, P530, DOI 10.1001/archpsyc.63.5.530
  14. Harari O, 2014, BIOL PSYCHIAT, V75, P723, DOI 10.1016/j.biopsych.2013.11.032
  15. Ferreira ST, 2011, NEUROBIOL LEARN MEM, V96, P529, DOI 10.1016/j.nlm.2011.08.003
  16. Di Prisco GV, 2014, NAT NEUROSCI, V17, P1073, DOI 10.1038/nn.3754
  17. Hynd MR, 2004, J NEUROCHEM, V89, P240, DOI 10.1111/j.1471-4159.2003.02330.x
  18. Paula-Lima AC, 2013, J NEUROCHEM, V126, P191, DOI 10.1111/jnc.12304
  19. Tabaraud F, 2012, ACTA NEUROL SCAND, V125, P416, DOI 10.1111/j.1600-0404.2011.01592.x
  20. Mouton-Liger F, 2012, BIOL PSYCHIAT, V71, P829, DOI 10.1016/j.biopsych.2011.11.031
  21. Wolosker H, 2008, FEBS J, V275, P3514, DOI 10.1111/j.1742-4658.2008.06515.x
  22. Radzishevsky I, 2013, CURR OPIN CLIN NUTR, V16, P72, DOI 10.1097/MCO.0b013e32835a3466
  23. Jankowsky JL, 2001, BIOMOL ENG, V17, P157, DOI 10.1016/S1389-0344(01)00067-3
  24. Ledo JH, 2013, MOL PSYCHIATR, V18, P1053, DOI 10.1038/mp.2012.168
  25. MORRIS JC, 1993, NEUROLOGY, V43, P2412
  26. McKhann GM, 2011, JAMA-J AM MED ASSOC, V305, P2458, DOI 10.1001/jama.2011.810
  27. Savage MJ, 2014, J NEUROSCI, V34, P2884, DOI 10.1523/JNEUROSCI.1675-13.2014
  28. Filali M, 2013, EUR J PHARMACOL, V701, P152, DOI 10.1016/j.ejphar.2012.12.018
  29. Li SM, 2011, J NEUROSCI, V31, P6627, DOI 10.1523/JNEUROSCI.0203-11.2011
  30. Hulstaert F, 1999, NEUROLOGY, V52, P1555
  31. Xia WM, 2009, ARCH NEUROL-CHICAGO, V66, P190, DOI 10.1001/archneurol.2008.565
  32. Fisher G, 1998, AMINO ACIDS, V15, P263, DOI 10.1007/BF01318865
  33. Grinberg Lea Tenenholz, 2007, Cell and Tissue Banking, V8, P151, DOI 10.1007/s10561-006-9022-z
  34. Selkoe DJ, 2012, SCIENCE, V337, P1488, DOI 10.1126/science.1228541
  35. Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469
  36. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  37. Wilson RS, 2002, NEUROLOGY, V59, P364
  38. Lourenco MV, 2013, CELL METAB, V18, P831, DOI 10.1016/j.cmet.2013.11.002
  39. Mishizen-Eberz AJ, 2004, NEUROBIOL DIS, V15, P80, DOI 10.1016/j.nbd.2003.09.016
  40. De Felice FG, 2007, J BIOL CHEM, V282, P11590, DOI 10.1074/jbc.M607483200
  41. Wolosker H, 2013, BIOCHEM SOC T, V41, P1546, DOI 10.1042/BST20130220
  42. Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448
  43. Li SM, 2009, NEURON, V62, P788, DOI 10.1016/j.neuron.2009.05.012
  44. Hampel H, 2008, ALZHEIMERS DEMENT, V4, P38, DOI [10.1016/j.jalz.2007.08.006, 10.1016/j.ja1z.2007.08.006]
  45. Bado P, 2011, PSYCHOPHARMACOLOGY, V218, P461, DOI 10.1007/s00213-011-2330-4
  46. Brito-Moreira J, 2011, CURR ALZHEIMER RES, V8, P552
  47. Talantova M, 2013, P NATL ACAD SCI USA, V110, pE2518, DOI 10.1073/pnas.1306832110
  48. KUMASHIRO S, 1995, BRAIN RES, V681, P117, DOI 10.1016/0006-8993(95)00307-C
  49. NAGATA Y, 1995, BRAIN RES BULL, V38, P181, DOI 10.1016/0361-9230(95)00087-U
  50. CHOUINARD ML, 1993, J NEUROCHEM, V61, P1561, DOI 10.1111/j.1471-4159.1993.tb13657.x
  51. McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005
  52. Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911
  53. Blennow K, 2010, NAT REV NEUROL, V6, P131, DOI 10.1038/nrneurol.2010.4
  54. Roselli F, 2005, J NEUROSCI, V25, P11061, DOI 10.1523/JNEUROSCI.3034-05.2005
  55. Jack CR, 2011, ALZHEIMERS DEMENT, V7, P257, DOI 10.1016/j.jalz.2011.03.004
  56. Esposito S, 2012, AGING CELL, V11, P588, DOI 10.1111/j.1474-9726.2012.00822.x
  57. HASHIMOTO A, 1992, FEBS LETT, V296, P33, DOI 10.1016/0014-5793(92)80397-Y
  58. Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621
  59. Smith DL, 2009, P NATL ACAD SCI USA, V106, P16877, DOI 10.1073/pnas.0908706106
  60. Wolosker H, 2012, AMINO ACIDS, V43, P1895, DOI 10.1007/s00726-012-1370-3
  61. Decker H, 2010, J NEUROCHEM, V115, P1520, DOI 10.1111/j.1471-4159.2010.07058.x
  62. Armstrong RA, 2000, NEUROPATHOLOGY, V20, P31, DOI 10.1046/j.1440-1789.2000.00284.x
  63. BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239
  64. Dauvilliers YA, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00119
  65. DeKosky Steven T, 2011, Alzheimers Dement, V7, pe1, DOI 10.1016/j.jalz.2010.12.007
  66. Dumurgier J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053587
  67. Fagan AM, 2014, SCI TRANSL MED, V6
  68. Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BRM.41.4.1149
  69. Ferretti REL, 2010, DEMENT NEUROPSYCHOL, V4, P138
  70. Guercio GD, 2014, NEUROPHARMACOLOGY, V86, P1, DOI 10.1016/j.neuropharm.2014.06.021
  71. Ikonemevic MD, 1999, EXP NEUROL, V160, P194, DOI 10.1006/exnr.1999.7196
  72. Lehmann S, 2014, ALZHEIMERS RES THER, V6, P1
  73. Lehmann S, 2014, ALZHEIMERS DEMENT, V10, pe392
  74. Mucke L, 2012, COLD SPRING HARBOR P, V2, P1
  75. Parsons CG, 2013, NEUROTOX RES, V24, P358, DOI 10.1007/s12640-013-9398-z
  76. Tarawneh R, 2012, COLD SPRING HARB PER, V2, P1
  77. Wu S-Z, 2004, J NEUROINFLAMM, V1, P1

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/22